SEC Comment Letter for Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196) (CANF) — Jun 5, 2017
Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196)
Date: June 5, 2017 · CIK: 0001536196 · Accession: 0000000000-17-019537
AI Filing Summary & Sentiment
Reasoning
Letter
June 5, 2017 Dr. Pnina Fishman Chief Executive Officer Can-Fite Biopharma Ltd. 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, Israel Can-Fite BioPharma Ltd. Registration Statement on Form F-1 Filed May 30, 2017 File No. 333-218336Re: Dear Dr. Fishman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Gary Emmanuel
Show Raw Text
June 5, 2017
Dr. Pnina Fishman
Chief Executive Officer
Can-Fite Biopharma Ltd.
10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
Can-Fite BioPharma Ltd.
Registration Statement on Form F-1
Filed May 30, 2017
File No. 333-218336Re:
Dear Dr. Fishman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at (202) 551-6761 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Gary Emmanuel